If you have been reading about Gastric protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
The bite is immediately followed by the local pain of a burning character; the limb soon swells and becomes discolored, and within one to three hours great prostration, accompanied by vomiting, and often diarrhea, sets in. Cold, clammy perspiration is usual. The pulse becomes extremely feeble, and slight dyspnoea and restlessness may be seen. In severe cases, which occur mostly in children, the pulse may become imperceptible and the extremities cold; the patient may pass into coma. In from twelve to twenty-four hours these severe constitutional symptoms usually pass off; but in the meantime, the swelling and discoloration have spread enormously. The limb becomes phlegmonous and occasionally suppurates. Within a few days recovery usually occurs somewhat suddenly, but death may result from the severe depression or from the secondary effects of suppuration. That cases of death, in adults as well as in children, are not infrequent in some parts of the Continent is mentioned in the last chapter of this Introduction. The Viperidae differ much among themselves in the toxicity of their venoms. Some, such as the Indian Russell's viper (Daboia russelli) and saw-scaled viper (E. carinatus); the American rattlesnakes (Crotalus spp.), bushmasters (Lachesis spp.), and lanceheads (Bothrops spp.); and the African adders (Bitis spp.), night adders (Causus spp.), and horned vipers (Cerastes spp.), cause fatal results unless a remedy is speedily applied.
=== Desiccation === Desiccation is also known as dehydration. It is the state of extreme dryness or the process of extreme drying. Some microorganisms like bacteria, yeasts and molds require water for their growth. Desiccation dries up the water content thus inhibiting microbial growth. On the availability of water, the bacteria resume their growth, thus desiccation does not completely inhibit bacterial growth. The instrument used to carry out this process is called a desiccator. This process is widely used in the food industry and is an efficient method for food preservation. Desiccation is also largely used in the pharmaceutical industry to store vaccines and other products.
S3: The S3 pocket is located on the rim of the S1 pocket and is flat and exposed to the solvent. This pocket is not as important as S1 and S4. S4: The S4 pocket is hydrophobic in nature and the floor of the pocket is formed by Trp-215 residue. The residues Phe-174 and Tyr-99 of FXa join Trp-215 to form an aromatic box that is able to bind aliphatic, aromatic and positively charged fragments. Because of the binding to positively charged entities, it can be described as a cation hole.
Sources: en.wikipedia.org
82nd Airborne Division Division Headquarters 325th Glider Infantry Regiment (325th GIR) (received the 2nd Battalion, 401st GIR, 101st Airborne Division on 1 March 1945, which became the 3rd Battalion, 325th GIR) Headquarters and Headquarters Company 2× glider infantry battalions (3× glider infantry battalions from 1 March 1945) each battalion consists of: 1× Headquarters and Headquarters Company, 3× Rifle companies Anti-Tank Company (assigned 1 March 1945) Service Company 504th Parachute Infantry Regiment (504th PIR) Headquarters and Headquarters Company 3× parachute infantry battalions each battalion consists of: 1× Headquarters and Headquarters Company, 3× Rifle companies Service Company 505th Parachute Infantry Regiment (505th PIR) same organization as 504th Parachute Infantry Regiment 82nd Airborne Division Artillery Headquarters Battery 319th Glider Field Artillery Battalion Headquarters and Headquarters and Service Battery 2× Batteries (M1 75mm pack howitzers) 320th Glider Field Artillery Battalion same organization as 319th Glider Field Artillery Battalion 376th Parachute Field Artillery Battalion Headquarters and Headquarters and Service Battery 3× Batteries (M1 75mm pack howitzers) Anti-Aircraft and Anti-Tank Battery (M2 .50-caliber machine guns, M3 37mm Anti-Tank guns, and M1 Bazookas) 456th Parachute Field Artillery Battalion same organization as 376th Parachute Field Artillery Battalion Special Troops (Headquarters activated 1 March 45, until then the units below were directly under the Division Headquarters) Headquarters Company, 82nd Airborne Division 82nd Airborne Signal Company 407th Airborne Quartermaster Company 782nd Airborne Ordnance Company Reconnaissance Platoon (assigned 1 March 45) Military Police Platoon Band (assigned 1 March 45) 80th Airborne Anti-Aircraft Artillery Battalion Headquarters and Headquarters Detachment 3× Automatic weapon batteries (M3 37mm Anti-Tank guns and from June 1944 M1 57mm anti-tank guns) 3× Machine gun batteries (M2 .50-caliber machine guns) 307th Airborne Engineer Battalion Headquarters and Headquarters and Service Company 2× Glider engineer companies 1× Parachute engineer company 82nd Parachute Maintenance Company (provisional unit made permanent on 1 March 1945) 307th Airborne Medical Company Attached paratrooper units:
Motion of the cephalopods is usually backward as water is forced out anteriorly through the hyponome, but direction can be controlled somewhat by pointing it in different directions. Some cephalopods accompany this expulsion of water with a gunshot-like popping noise, thought to function to frighten away potential predators. Cephalopods employ a similar method of propulsion despite their increasing size (as they grow) changing the dynamics of the water in which they find themselves. Thus their paralarvae do not extensively use their fins (which are less efficient at low Reynolds numbers) and primarily use their jets to propel themselves upwards, whereas large adult cephalopods tend to swim less efficiently and with more reliance on their fins.
== Further reading == Martin, Wednesday, PhD (2009). Stepmonster: A New Look at Why Real Stepmothers Think, Feel, and Act the Way We Do. New York: Houghton Mifflin Harcourt. Ulrike Zartler, Valerie Heinz-Martin, Oliver Arránz Becker (Eds.) (2015). Family Dynamics After Separation: A Life Course Perspective on Post-Divorce Families. Special Issue ZfF, Volume 10, Barbara Budrich, ISBN 978-3-8474-0686-0.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.